US FDA grants fast track designation to EDDC’s antibody-drug conjugate EBC-129 to treat pancreatic ductal adenocarcinoma: Singapore Thursday, May 29, 2025, 12:00 Hrs [IST] The E ...

Singapore's Experimental Drug Development Centre (EDDC) has achieved a significant milestone: the U.S. FDA has granted Fast Track designation to EBC-129, a ...

EBC-129 is the first made-in-Singapore antibody-drug conjugate (ADC) to enter clinical development. It selectively targets a tumour-specific N-glycosylated epitope on both CEACAM5 and CEACAM6.

In the long battle to create an effective HIV vaccine, scientists have made a major leap forward. A new study shows that a ...

About Adagene Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer ...

Autoimmune diseases develop when the immune system mistakenly attacks the body’s own tissues by recognizing self-antigens as ...

Pharmacokinetic and safety data from healthy volunteers anticipated around YE 2025 On track to initiate a Phase 2 study in 1H ...

Debates over AI antibody design terminology have clouded the industry’s shared mission of bringing better therapeutics to the ...

Q1 2025 Earnings Call Transcript May 15, 2025 Operator: Thank you for standing by. And welcome to Invivyd’s First Quarter ...

Detailed price information for Immunoprecise Antibodies Ltd (IPA-Q) from The Globe and Mail including charting and trades.

Announced in early January 2025, ProMIS initiated PRECISE-AD based on the encouraging results from the Phase 1a trial of PMN310 and has since completed enrollment of the first cohort of patients and ...